+77.8%
CSX vs MRNA
+257.4%
-179.6%
-29.4%
Performance
Returns, benchmark comparison, and relative performance.
Performance by timeframe
Returns for 3y.
| Period | Portfolio | MRNA | Excess | Alpha |
|---|---|---|---|---|
| 1D | +1.6% | -0.9% | +2.5% | +1.6% |
| 7D | -0.3% | -3.8% | +3.5% | -0.2% |
| 30D | +8.7% | +16.4% | -7.7% | +8.3% |
| 3M | +4.2% | +310.6% | -306.4% | -1.0% |
| 6M | +16.7% | +370.3% | -353.6% | +9.0% |
| YTD | +44.5% | +743.3% | -698.8% | +27.5% |
| 1Y | +50.3% | +841.7% | -791.4% | +31.0% |
| All | +77.8% | +257.4% | -179.6% | +54.1% |
Cumulative growth
Daily Returns
Daily percentage return beside MRNA.
Daily Out/Under-Performance
Portfolio return minus MRNA return. Positive bars indicate outperformance.
Daily Alpha
Portfolio daily return minus β × MRNA return. Early observations use the first valid beta; later observations use the trailing beta estimated for each date.
Cumulative Out/Under-Performance
Relative wealth over 3y: compounded portfolio wealth divided by compounded MRNA wealth, less one. Both series rebase at the selected span's start.
Cumulative Alpha
Compounded beta-adjusted residual returns apply the first valid beta to early observations, then the trailing beta ending on each date.
Updating return analytics…
3y analysis · Full analysis span regression · 6 months rolling